Question 1

How many shares of GENE does CITADEL ADVISORS LLC own?

Accepted Answer

CITADEL ADVISORS LLC previously held 0 shares of GENE (GENETIC TECHNOLOGIES LTD) before exiting the position in 2024-Q4.

Question 2

What is CITADEL ADVISORS LLC's GENE position worth?

Accepted Answer

CITADEL ADVISORS LLC's GENE position was last reported at $0 in 2024-Q4 before the exit.

Question 3

Is CITADEL ADVISORS LLC buying or selling GENE?

Accepted Answer

In 2024-Q4, CITADEL ADVISORS LLC exited their GENE position entirely (-100.0% change in shares).

Question 4

When did CITADEL ADVISORS LLC first buy GENE?

Accepted Answer

Based on available 13F filings, CITADEL ADVISORS LLC first reported a position in GENE in 2020-Q4. They have held the position across 12 quarters.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2024-Q4 Latest	Exited	0	-100.0%	$0	0.0%	—	0
2024-Q3	New	682	-	$510	0.0%	—	17
2023-Q2	Exited	0	-100.0%	$0	0.0%	—	0
2023-Q1	New	1,208	-	$1,413	0.0%	—	17
2022-Q3	Exited	0	-100.0%	$0	0.0%	—	0
2022-Q2	Increased	36,117	+202.0%	$41,000	0.0%	—	22
2022-Q1	Decreased	11,958	-66.8%	$24,000	0.0%	—	0
2021-Q4	Decreased	36,055	-10.9%	$68,000	0.0%	—	0
2021-Q3	Increased	40,472	+50.7%	$125,000	0.0%	—	21
2021-Q2	Decreased	26,852	-74.4%	$114,000	0.0%	—	0
2021-Q1	Increased	104,990	+336.1%	$438,000	0.0%	—	39
2020-Q4	New	24,073	-	$87,000	0.0%	—	33

GENE12 quarters

GENE
12 quarters